MIRA PHARMACEUTICALS, INC.
MIRA evidence brief
What we can confirm
- Market Cap:
- $32.5M
What it means
What to watch
Prepared research question
What matters most for MIRA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · MIRA
MIRA Pharmaceuticals, Inc. (MIRA) is a clinical-stage biopharmaceutical company developing oral small-molecule therapeutics for pain, obesity, and addiction, with lead candidate Ketamir-2 advancing toward Phase 2a for chemotherapy-induced peripheral neuropathy.
Key risk: Cash runway limited
Market Cap
$32.5M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
MIRA Pharmaceuticals, Inc. (MIRA) is a clinical-stage biopharmaceutical company developing oral small-molecule therapeutics for pain, obesity, and addiction, with lead candidate Ketamir-2 advancing toward Phase 2a for chemotherapy-induced peripheral neuropathy.
- Lead candidate Ketamir-2 completed Phase 1 SAD/MAD cohorts with no serious adverse events or dose-limiting toxicities reported [sec_mda · as of 2026-08-12].
- Phase 2a protocol for Ketamir-2 in chemotherapy-induced peripheral neuropathy (CIPN) has been submitted to FDA and is under IRB review at a leading cancer research institution [news · published 2026-09-17].
- MIRA-55, a non-opioid oral candidate for inflammatory pain, reported positive 7-day toxicology results and is targeting an IND submission in Q1 2027 [news · published 2026-09-01].
- SKNY-1, an oral drug candidate for obesity and addiction, demonstrated favorable oral bioavailability and brain penetration in preclinical studies [news · published 2026-07-06].
- Cash and equivalents were $3.6M as of 2026-06-30, with net income of -$1.2M and shareholders' equity of $8.2M [sec].
What works
- Ketamir-2 has completed Phase 1 with no serious adverse events or dose-limiting toxicities, supporting advancement to Phase 2a [sec_mda · as of 2026-08-12].
- The DEA has concluded that neither Ketamir-2 nor MIRA-55 would be controlled substances, potentially easing regulatory hurdles [sec_mda · as of 2026-03-31].
- SKNY-1 has shown differentiated CNS safety without anxiety-related effects in preclinical models, distinguishing it from earlier CB1-targeting agents [sec_mda · as of 2026-08-12].
What to weigh
- Cash and equivalents were only $3.6M as of 2026-06-30, and the company anticipates additional capital may be required to support ongoing activities [sec_mda · as of 2026-08-12].
- The company has no approved products and is dependent on successful clinical development and eventual monetization of its candidates [sec_mda · as of 2026-08-12].
- Phase 2a initiation for Ketamir-2 is subject to FDA clearance, site readiness, and other regulatory and operational factors, creating timeline uncertainty [sec_mda · as of 2026-08-12].
From the filings
Quoted directly from source documents.
Ketamir-2 Phase 1 safety data shows no serious adverse events or dose-limiting toxicities
“Based on preliminary safety data reviewed to date, no serious adverse events or dose-limiting toxicities have been reported.”
SEC MD&A · August 12, 2026
SKNY-1 demonstrated favorable oral bioavailability and brain penetration
“The studies demonstrated favorable oral bioavailability together with reproducible systemic exposure and robust brain penetration”
News · July 6, 2026
Risks & what to watch (3)›
Key risks
- Cash runway limited — Cash of $3.6M as of 2026-06-30 may be insufficient to fund operations through planned milestones without additional financing [sec].
- No approved products — Company has no marketed products and relies on successful clinical development and eventual monetization of candidates [sec_mda · as of 2026-08-12].
- Phase 2a timeline uncertainty — Initiation of Ketamir-2 Phase 2a depends on FDA clearance, site readiness, and other factors, creating schedule risk [sec_mda · as of 2026-08-12].
What to watch
- Initiation of Ketamir-2 Phase 2a clinical trial in CIPN, targeted for Q1 2027 [sec_mda · as of 2026-08-12].
- IND submission for MIRA-55, targeted for Q1 2027 [news · published 2026-09-01].
- Progress of SKNY-1 CMC and nonclinical development toward regulatory filing [sec_mda · as of 2026-08-12].
- Company's ability to secure additional capital to fund ongoing operations and development [sec_mda · as of 2026-08-12].
Sources: News · SEC MD&A · Generated October 14, 2026 · How we verify sources →
Run MIRA PHARMACEUTICALS, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available MIRA PHARMACEUTICALS, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
26
Total value held
$2.3M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 693,912 | $742K |
| cross staff investments inc | 359,401 | $385K |
| geode capital management, llc | 290,890 | $311K |
| vanguard fiduciary trust co | 169,483 | $181K |
| blackrock, inc. | 112,346 | $120K |
| suncoast equity management | 90,645 | $97K |
| northern trust corp | 67,698 | $72K |
| first american bank | 60,000 | $64K |
| state street corp | 49,100 | $53K |
| xtx topco ltd | 37,573 | $40K |
Showing top 10 of 26 institutional holders of MIRA PHARMACEUTICALS, INC.. Open the full 13F history after sign-in.
Short Interest
as of Apr 20, 2026- % of float
- 1.1%
- Days to cover
- 2.5
- Shares short
- 437,032
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
MIRA short interestGovernance
Frequently asked questions
What is the AI investment thesis for MIRA PHARMACEUTICALS, INC.?
MIRA Pharmaceuticals, Inc. (MIRA) is a clinical-stage biopharmaceutical company developing oral small-molecule therapeutics for pain, obesity, and addiction, with lead candidate Ketamir-2 advancing toward Phase 2a for chemotherapy-induced peripheral neuropathy.
Who is the CEO of MIRA PHARMACEUTICALS, INC.?
Mr. Erez Aminov is the chief executive officer of MIRA PHARMACEUTICALS, INC. (MIRA).
Where is MIRA PHARMACEUTICALS, INC. headquartered?
MIRA PHARMACEUTICALS, INC. (MIRA) is headquartered in Miami, FL, United States.
What therapeutic areas does MIRA PHARMACEUTICALS, INC. focus on?
MIRA PHARMACEUTICALS, INC. develops therapies across Metabolic, Psychiatry.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.